目的 探討左旋多巴聯(lián)合普拉克索治療帕金森病的臨床療效及安全性。方法 選取2015年8月—2017年12月于南通市第一人民醫(yī)院神經(jīng)內(nèi)科門(mén)診或住院診治的帕金森病患者150例，采用隨機(jī)法分為觀察組（80例）和對(duì)照組（70例），對(duì)照組患者僅給予左旋多巴進(jìn)行治療，觀察組患者給予左旋多巴聯(lián)合普拉克索進(jìn)行治療，持續(xù)服藥12周，比較兩組患者帕金森病綜合評(píng)估量表（UPDRS）Ⅱ和UPDRS Ⅲ、漢密頓抑郁量表（HAMD）及不良反應(yīng)的發(fā)生率。結(jié)果 治療前，兩組患者的UPDRS Ⅱ和UPDRS Ⅲ評(píng)分相比，差異無(wú)統(tǒng)計(jì)學(xué)意義；經(jīng)治療后，兩組患者UPDRS Ⅱ和UPDRS Ⅲ評(píng)分均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；與對(duì)照組相比，觀察組患者UPDRS Ⅱ和UPDRS Ⅲ評(píng)分顯著低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者的HAMD評(píng)分顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；與對(duì)照組治療后相比，觀察組患者的HAMD評(píng)分顯著降低，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組患者不良反應(yīng)發(fā)生率為13例（16.25%），對(duì)照組患者不良反應(yīng)發(fā)生率為9例（12.86%），差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 左旋多巴聯(lián)合普拉克索治療帕金森病的臨床療效較好，且安全可靠。

Objective To investigate the clinical efficacy and safety of levodopa combined with pramipexole in the treatment of Parkinson's Disease. Methods 150 cases Parkinson's Disease patients from August 2015 to December 2017 in the First People's Hospital of Nantong were randomly divided into treatment group (80 cases) and control group (70 cases), the treatment group was given levodopa combined with pramipexole, the control group was given levodopa, compared with the unified Parkinson's Disease rating scale Ⅱ, unified Parkinson's Disease rating scale Ⅲ, hamilton depression scale and incidence of adverse reaction. Results Before treatment, compared with the UPDRS Ⅱ, UPDRS Ⅲ and HAMD score of the two group, the difference was not statistically significant. After treatment, compared with the control group, the UPDRS Ⅱ, UPDRS Ⅲ and HAMD score significantly decreased of the treatment group, with significant difference (P<0.05). The incidence of adverse reaction of the treatment group is 13 cases (16.25%), the incidence of adverse reaction of the control group is 9 case (12.86%), compared with the two groups, the difference was not statistically significant.Conclusion Levodopa combined with pramipexole has good effect in the treatment of Parkinson's Disease, and the safety is high.

2015年度南通市民生示范推廣項(xiàng)目（MS32015033）